(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best 15 Applications for Efficiency and Association - 2UK consumer confidence plunges amid escalating Iran conflict
- 3Jenny & Dave Marrs Mourn Loss of Former ‘Fixer to Fabulous: Italiano’ Guest
- 4Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- 5Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- Warning for snow and ice extended
- Winter virus season so far is not too bad, but doctors worry about suffering to come
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- Europe picks companies to help build Argonaut moon lander
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Europe’s Airlines Run Low on Fuel
